CCEL (cryo-cell.com) יחס שווי שוק לשווי בספרים

The price action of Cryo-Cell International (CCEL) serves as an indicator of business development driven by high customer loyalty and its exclusive status as the largest private biobank in the US. The company's strategy is based on expanding its laboratory base and increasing profits from long-term contracts, which constitutes -2.42. Revenue is generated through initial fees during biomaterial collection and subsequent annual payments for the cryopreservation of stem cells.

This indicator compares the current market value of Cryo-Cell International (CCEL) with its actual net assets to identify whether the business is overvalued or undervalued. The price-to-book ratio trend allows for the tracking of fundamental trend reversals between quarterly reports. Stable demand for stem cell cryobanking makes the company's assets resilient to GDP volatility. Analyzing this chart helps determine the entry point, avoiding buying at the peak. Low values confirm high investment protection.